Status:
ENROLLING_BY_INVITATION
Healthcare Utilization and Economic Burden of Cardiomyopathy in China
Lead Sponsor:
China National Center for Cardiovascular Diseases
Conditions:
Cardiomyopathies
Economic Burden
Eligibility:
All Genders
18+ years
Brief Summary
Cardiomyopathy is the most common inherited cardiovascular disease, showing family aggregation, and it has a huge psychological and economic burden on family members. In this study, the investigators ...
Detailed Description
This study conducted a retrospective survey of hospitalized patients with cardiomyopathy aged ≥18 years in 13 centers in China from March 1, 2017 to March1, 2022. The investigators collected demograph...
Eligibility Criteria
Inclusion
- Hospitalized patients with primary discharge diagnosis meeting one of the following subtypes of cardiomyopathy were enrolled, including HCM, DCM, ACM, RCM, left ventricular non-compaction, cardiac amyloidosis, Fabry disease, Pompe disease, Danon disease, and PRKAG2 cardiac syndrome.
Exclusion
- none
Key Trial Info
Start Date :
March 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT06893731
Start Date
March 1 2017
End Date
April 1 2026
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai hospital, Beijing, Beijing 100037
Beijing, China